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Rationale 
The Established Status Epilepticus Treatment Trial (ESETT) is a randomized, double-blind clinical 
trial comparing fosphenytoin (FOS), levetiracetam (LEV) and sodium valproate (VPA) in patients 
with established status epilepticus (ESE). An ancillary study (ESETT PK-PD) will characterize 
how plasma concentrations of these 3 drugs relate to the likelihood of seizure cessation in children 
using exposure-response modeling. To do this, an individualized estimate of early drug exposure 
is required, but enrollment of children in an emergency setting limits the amount of blood per 
sample and the number of samples that can be collected. Hence, this study utilizes a sparse 
sampling approach: 1 sample collected within 20-50 min and the other between 60-120 min after 
the start of study drug infusion. The objective of this work is to characterize the performance of a 
sparse sampling approach to predict concentrations at 60 min (C60) and partial AUCs from 20-
120 min (pAUC) post start of drug infusion in a simulated patient population generated from 
literature-based models for FOS, LEV, and VPA. 
Methods 
Literature-based population PK models were used to simulate samples from 500 pediatric patients 
(8 to 75 kg ) with rich concentration-time profiles (ie. “true”) for each study drug (20 mg/kg 
phenytoin-equivalents FOS, 40 mg/kg VPA, or 60 mg/kg LEV intravenous infusions over 10 
minutes).  One timepoint and corresponding concentration was randomly selected from each of 
the two sampling windows (20-50 min and 60-120 min after the start of study drug infusion) for 
100 randomly selected simulated patients with replacement.  We then developed population PK 
models using these 200 total concentrations from the 100 simulated patients (2 drug 
concentrations per subject).  The PK model used was one-compartment for FOS and VPA and 
two-compartment for LEV. The sparse-sampling model-predicted pAUC and C60 were correlated 
with the “true” pAUC and C60 (reference) values from the full set of simulated data.  As an 
alternative approach, the concentration at the randomly sampled timepoint in the first window 
C1(20-50min) was also compared with C60.  R was used for simulations (mrgsolve), statistical 
analyses and graphing and NONMEM v 7.3 (Non-Linear Mixed Effects Modeling Software, Icon 
Ltd) was used for PK population modeling. 
Results  
Despite using a mg/kg dosing scheme in children, approximately 3-fold variability in predicted 
exposure measures was found for all 3 drugs. For the sparse sampling approach, good correlation 
between the predicted pAUC and C60 and the “true” pAUC and C60 was observed with correlation 
coefficients (R) of 0.7-0.9 for all 3 drugs (p << 0.001). Using C1(10-50min) as an estimate of C60 
was inferior to the sparse-sampling population modeling approach (R= 0.76, 0.54, and 0.43 for 
FOS, VPA, and LEV, respectively).  
Conclusions 
We conclude that a sparse sampling approach can accurately predict metrics of early drug 
exposure. Simulations show that we expect approximately 3-fold variability in drug exposure 
which aligns well with the results from the sparse sampling model. The use of sparse PK sampling 
will allow for exposure-response modeling which will enable further investigation of factors 
affecting drug response in children with ESE when blood sampling is limited.  This approach can 
be explored in other emergent conditions and/or in children when blood sample limitations exist. 
 
 
I don’t know if the figures sent in the separate PowerPoint were going to be included in the abstract 
submission.  If so, the abbreviations should be reconciled, i.e., pAUC rather than AUCpred, C60 
rather than Conc upto 1hr or IPRED at 1hr, etc.  All horizontal axes should be labeled simulated 
and all vertical axes should be labeled predicted.   
